{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T04:04:17Z","timestamp":1730261057340,"version":"3.28.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,28]]},"DOI":"10.7759\/cureus.72587","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T03:39:03Z","timestamp":1730173143000},"source":"Crossref","is-referenced-by-count":0,"title":["Induced Native Phage Cocktails for Multi-microbial Activation Syndrome in Treatment-Resistant Illnesses"],"prefix":"10.7759","author":[{"given":"David A","family":"Jernigan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11121731","article-title":"Polymicrobial infections and biofilms: clinical significance and eradication strategies","volume":"11","author":"Anju VT","year":"2022","unstructured":"Anju VT, Busi S, Imchen M, et al.. Polymicrobial infections and biofilms: clinical significance and eradication strategies. Antibiotics (Basel). 2022, 11:1731. 10.3390\/antibiotics11121731","journal-title":"Antibiotics (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-018-06983-0","article-title":"First report of antimicrobial resistance pre-dates penicillin","volume":"562","author":"Stekel D","year":"2018","unstructured":"Stekel D. First report of antimicrobial resistance pre-dates penicillin. Nature. 2018, 562:192. 10.1038\/d41586-018-06983-0","journal-title":"Nature"},{"key":"ref3","article-title":"Penicillin's discovery and antibiotic resistance: lessons for the future?","volume":"29","author":"Lobanovska M","year":"2017","unstructured":"Lobanovska M, Pilla G. Penicillin's discovery and antibiotic resistance: lessons for the future?. Yale J Biol Med. 2017, 29:135-45.","journal-title":"Yale J Biol Med"},{"key":"ref4","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"8","year":"2016","unstructured":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015. a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016, 8:1459-544.","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_329_17","article-title":"Iatrogenesis: a review on nature, extent, and distribution of healthcare hazards","volume":"7","author":"Peer RF","year":"2018","unstructured":"Peer RF, Shabir N. Iatrogenesis: a review on nature, extent, and distribution of healthcare hazards. J Family Med Prim Care. 2018, 7:309-14. 10.4103\/jfmpc.jfmpc_329_17","journal-title":"J Family Med Prim Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2019.1706425","article-title":"Oral antibiotic use and chronic disease: long-term health impact beyond antimicrobial resistance and Clostridioides difficile","volume":"11","author":"Queen J","year":"2020","unstructured":"Queen J, Zhang J, Sears CL. Oral antibiotic use and chronic disease: long-term health impact beyond antimicrobial resistance and Clostridioides difficile. Gut Microbes. 2020, 11:1092-103. 10.1080\/19490976.2019.1706425","journal-title":"Gut Microbes"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.315279","article-title":"Duration and life-stage of antibiotic use and risks of all-cause and cause-specific mortality: prospective cohort study","volume":"126","author":"Heianza Y","year":"2020","unstructured":"Heianza Y, Ma W, Li X, et al.. Duration and life-stage of antibiotic use and risks of all-cause and cause-specific mortality: prospective cohort study. Circ Res. 2020, 126:364-73. 10.1161\/CIRCRESAHA.119.315279","journal-title":"Circ Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.643214","article-title":"The human gut phageome: origins and roles in the human gut microbiome","volume":"11","author":"Townsend EM","year":"2021","unstructured":"Townsend EM, Kelly L, Muscatt G, Box JD, Hargraves N, Lilley D, Jameson E. The human gut phageome: origins and roles in the human gut microbiome. Front Cell Infect Microbiol. 2021, 11:643214. 10.3389\/fcimb.2021.643214","journal-title":"Front Cell Infect Microbiol"},{"key":"ref9","article-title":"The Hunterian oration on Louis Pasteur's final judgement. Host reaction, soil or terrain","volume":"99-100","author":"James DG","year":"1982","unstructured":"James DG. The Hunterian oration on Louis Pasteur's final judgement. Host reaction, soil or terrain. Trans Med Soc Lond. 1982, 99-100:131-47.","journal-title":"Trans Med Soc Lond"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00830","article-title":"The sources of chemical contaminants in food and their health implications","volume":"8","author":"Rather IA","year":"2017","unstructured":"Rather IA, Koh WY, Paek WK, Lim J. The sources of chemical contaminants in food and their health implications. Front Pharmacol. 2017, 8:830. 10.3389\/fphar.2017.00830","journal-title":"Front Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3934\/microbiol.2018.3.482","article-title":"An overview of the antimicrobial resistance mechanisms of bacteria","volume":"4","author":"Reygaert WC","year":"2018","unstructured":"Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018, 4:482-501. 10.3934\/microbiol.2018.3.482","journal-title":"AIMS Microbiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2018.07.003","article-title":"Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery","volume":"44","author":"Kriss M","year":"2018","unstructured":"Kriss M, Hazleton KZ, Nusbacher NM, Martin CG, Lozupone CA. Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery. Curr Opin Microbiol. 2018, 44:34-40. 10.1016\/j.mib.2018.07.003","journal-title":"Curr Opin Microbiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/mbo3.1260","article-title":"Impact of antibiotics on the human microbiome and consequences for host health","volume":"11","author":"Patangia DV","year":"2022","unstructured":"Patangia DV, Anthony Ryan C, Dempsey E, Paul Ross R, Stanton C. Impact of antibiotics on the human microbiome and consequences for host health. Microbiologyopen. 2022, 11:e1260. 10.1002\/mbo3.1260","journal-title":"Microbiologyopen"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nature09199","article-title":"Viruses in the faecal microbiota of monozygotic twins and their mothers","volume":"466","author":"Reyes A","year":"2010","unstructured":"Reyes A, Haynes M, Hanson N, Angly FE, Heath AC, Rohwer F, Gordon JI. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature. 2010, 466:334-8. 10.1038\/nature09199","journal-title":"Nature"},{"key":"ref15","article-title":"Small intestinal bacterial overgrowth","author":"Sorathia SJ","year":"2023","unstructured":"Sorathia SJ, Chippa V, Rivas JM. Small intestinal bacterial overgrowth. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2007\/976850","article-title":"Phage as an antimicrobial agent: d'Herelle's heretical theories and their role in the decline of phage prophylaxis in the West","volume":"18","author":"Fruciano DE","year":"2007","unstructured":"Fruciano DE, Bourne S. Phage as an antimicrobial agent: d'Herelle's heretical theories and their role in the decline of phage prophylaxis in the West. Can J Infect Dis Med Microbiol. 2007, 18:19-26. 10.1155\/2007\/976850","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ph14070634","article-title":"The many applications of engineered bacteriophages-an overview","volume":"14","author":"Gibb B","year":"2021","unstructured":"Gibb B, Hyman P, Schneider CL. The many applications of engineered bacteriophages-an overview. Pharmaceuticals (Basel). 2021, 14:634. 10.3390\/ph14070634","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01258-23","article-title":"Designing phage cocktails to combat the emergence of bacteriophage-resistant mutants in multidrug-resistant Klebsiella pneumoniae","volume":"12","author":"Yoo S","year":"2024","unstructured":"Yoo S, Lee K-M, Kim N, Vu TN, Abadie R, Yong D. Designing phage cocktails to combat the emergence of bacteriophage-resistant mutants in multidrug-resistant Klebsiella pneumoniae. Microbiol Spectr. 2024, 12:e0125823. 10.1128\/spectrum.01258-23","journal-title":"Microbiol Spectr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4161\/bact.1.2.14590","article-title":"Pros and cons of phage therapy","volume":"1","author":"Loc-Carrillo C","year":"2011","unstructured":"Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011, 1:111-4. 10.4161\/bact.1.2.14590","journal-title":"Bacteriophage"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9102049","article-title":"The case against antibiotics and for anti-virulence therapeutics","volume":"9","author":"Hotinger JA","year":"2021","unstructured":"Hotinger JA, Morris ST, May AE. The case against antibiotics and for anti-virulence therapeutics. Microorganisms. 2021, 9:2049. 10.3390\/microorganisms9102049","journal-title":"Microorganisms"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701745","article-title":"Contribution of the immune response to phage therapy","volume":"200","author":"Krut O","year":"2018","unstructured":"Krut O, Bekeredjian-Ding I. Contribution of the immune response to phage therapy. J Immunol. 2018, 200:3037-44. 10.4049\/jimmunol.1701745","journal-title":"J Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.08.003","article-title":"The gut virome database reveals age-dependent patterns of virome diversity in the human gut","volume":"28","author":"Gregory AC","year":"2020","unstructured":"Gregory AC, Zablocki O, Zayed AA, Howell A, Bolduc B, Sullivan MB. The gut virome database reveals age-dependent patterns of virome diversity in the human gut. Cell Host Microbe. 2020, 28:724-40.e8. 10.1016\/j.chom.2020.08.003","journal-title":"Cell Host Microbe"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65739","article-title":"Adjunctive testing using biospectral emission sequencing: bioregulatory intelligence technology in parallel with the goals of artificial intelligence in medicine","volume":"16","author":"Jernigan DA","year":"2024","unstructured":"Jernigan DA. Adjunctive testing using biospectral emission sequencing: bioregulatory intelligence technology in parallel with the goals of artificial intelligence in medicine. Cureus. 2024, 16:e65739. 10.7759\/cureus.65739","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ph16101467","article-title":"Bacteriophages and their host range in multidrug-resistant bacterial disease treatment","volume":"16","author":"Chung KM","year":"2023","unstructured":"Chung KM, Liau XL, Tang SS. Bacteriophages and their host range in multidrug-resistant bacterial disease treatment. Pharmaceuticals (Basel). 2023, 16:1467. 10.3390\/ph16101467","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/21597081.2016.1270090","article-title":"F\u00e9lix Hubert d'Herelle (1873-1949): history of a scientific mind","volume":"6","author":"Summers WC","year":"2016","unstructured":"Summers WC. F\u00e9lix Hubert d'Herelle (1873-1949): history of a scientific mind. Bacteriophage. 2016, 6:e1270090. 10.1080\/21597081.2016.1270090","journal-title":"Bacteriophage"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20014","article-title":"Induced native phage therapy for the treatment of Lyme disease and relapsing fever: a retrospective review of first 14 months in one clinic","volume":"13","author":"Jernigan DA","year":"2021","unstructured":"Jernigan DA, Hart MC, Dodd KK, Jameson S, Farney T. Induced native phage therapy for the treatment of Lyme disease and relapsing fever: a retrospective review of first 14 months in one clinic. Cureus. 2021, 13:e20014. 10.7759\/cureus.20014","journal-title":"Cureus"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.16-0434","article-title":"The Jarisch-Herxheimer reaction after antibiotic treatment of spirochetal infections: a review of recent cases and our understanding of pathogenesis","volume":"96","author":"Butler T","year":"2017","unstructured":"Butler T. The Jarisch-Herxheimer reaction after antibiotic treatment of spirochetal infections: a review of recent cases and our understanding of pathogenesis. Am J Trop Med Hyg. 2017, 96:46-52. 10.4269\/ajtmh.16-0434","journal-title":"Am J Trop Med Hyg"},{"key":"ref28","article-title":"Chapter 15. Mixed infections of intestinal viruses and bacteria in humans","author":"Marshall JA","year":"2002","unstructured":"Marshall JA. Chapter 15. Mixed infections of intestinal viruses and bacteria in humans. Polymicrobial Diseases. Brogden KA, Guthmiller JM (ed): ASM Press, Washington, D.C.; 2002."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10030279","article-title":"Phage \u03c6AB6-borne depolymerase combats Acinetobacter baumannii biofilm formation and infection","volume":"10","author":"Shahed-Al-Mahmud M","year":"2021","unstructured":"Shahed-Al-Mahmud M, Roy R, Sugiokto FG, Islam MN, Lin MD, Lin LC, Lin NT. Phage \u03c6AB6-borne depolymerase combats Acinetobacter baumannii biofilm formation and infection. Antibiotics (Basel). 2021, 10:279. 10.3390\/antibiotics10030279","journal-title":"Antibiotics (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/femspd\/ftz011","article-title":"P. aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage-ciprofloxacin combination","volume":"77","author":"Henriksen K","year":"2019","unstructured":"Henriksen K, R\u00f8rbo N, Rybtke ML, et al.. P. aeruginosa flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage-ciprofloxacin combination. Pathog Dis. 2019, 77:011. 10.1093\/femspd\/ftz011","journal-title":"Pathog Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.825828.","article-title":"Bacteriophage-mediated control of biofilm: a promising new dawn for the future","volume":"4","author":"Chang C","year":"2022","unstructured":"Chang C, Yu X, Guo W, Guo C, Guo X, Li Q, Zhu Y. Bacteriophage-mediated control of biofilm: a promising new dawn for the future. Front Microbiol. 2022, 4:825828. 10.3389\/fmicb.2022.825828.","journal-title":"Front Microbiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9050268","article-title":"Phages for biofilm removal","volume":"9","author":"Ferriol-Gonz\u00e1lez C","year":"2020","unstructured":"Ferriol-Gonz\u00e1lez C, Domingo-Calap P. Phages for biofilm removal. Antibiotics (Basel). 2020, 9:268. 10.3390\/antibiotics9050268","journal-title":"Antibiotics (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3205\/dgkh000404","article-title":"Bacteriophages and related endolysins for reduction of microorganisms in the human body - a systematic review","volume":"17","author":"\u00d6zal D","year":"2022","unstructured":"\u00d6zal D, Arndt A, Thom\u00e9 M. Bacteriophages and related endolysins for reduction of microorganisms in the human body - a systematic review. GMS Hyg Infect Control. 2022, 17:Doc01. 10.3205\/dgkh000404","journal-title":"GMS Hyg Infect Control"},{"key":"ref34","unstructured":"PhagenCorp. Our research. (2024). Accessed: October 15, 2024: https:\/\/phagencorp.com\/our-research\/."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.97","article-title":"Bacteriophage endolysins as novel antimicrobials","volume":"7","author":"Schmelcher M","year":"2012","unstructured":"Schmelcher M, Donovan DM, Loessner MJ. Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 2012, 7:1147-71. 10.2217\/fmb.12.97","journal-title":"Future Microbiol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1139\/bcb-2020-0593","article-title":"The endless battle between phages and CRISPR-Cas systems in Streptococcus thermophilus","volume":"99","author":"Philippe C","year":"2021","unstructured":"Philippe C, Moineau S. The endless battle between phages and CRISPR-Cas systems in Streptococcus thermophilus. Biochem Cell Biol. 2021, 99:397-402. 10.1139\/bcb-2020-0593","journal-title":"Biochem Cell Biol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.065","article-title":"Bacterial retrons function in anti-phage defense","volume":"183","author":"Millman A","year":"2020","unstructured":"Millman A, Bernheim A, Stokar-Avihail A, et al.. Bacterial retrons function in anti-phage defense. Cell. 2020, 183:1551-61.e12. 10.1016\/j.cell.2020.09.065","journal-title":"Cell"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.825828","article-title":"Bacteriophage-mediated control of biofilm: a promising new dawn for the future","volume":"13","author":"Chang C","year":"2022","unstructured":"Chang C, Yu X, Guo W, Guo C, Guo X, Li Q, Zhu Y. Bacteriophage-mediated control of biofilm: a promising new dawn for the future. Front Microbiol. 2022, 13:825828. 10.3389\/fmicb.2022.825828","journal-title":"Front Microbiol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02685-15","article-title":"Bacteriophage can prevent encrustation and blockage of urinary catheters by Proteus mirabilis","volume":"60","author":"Nzakizwanayo J","year":"2015","unstructured":"Nzakizwanayo J, Hanin A, Alves DR, et al.. Bacteriophage can prevent encrustation and blockage of urinary catheters by Proteus mirabilis. Antimicrob Agents Chemother. 2015, 60:1530-6. 10.1128\/AAC.02685-15","journal-title":"Antimicrob Agents Chemother"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1117\/12.2648350","article-title":"Methylene blue photodynamic therapy of bacterial species found in human abscesses: planktonic, biofilm, and 3D silicone models","volume":"12358","author":"Chan H","year":"2023","unstructured":"Chan H, Pavelka MS Jr, Baran TM. Methylene blue photodynamic therapy of bacterial species found in human abscesses: planktonic, biofilm, and 3D silicone models. Proc SPIE Int Soc Opt Eng. 2023, 12358:1235805. 10.1117\/12.2648350","journal-title":"Proc SPIE Int Soc Opt Eng"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.000802","article-title":"Resistance is not futile: bacterial 'innate' and CRISPR-Cas 'adaptive' immune systems","volume":"165","author":"Fineran PC","year":"2019","unstructured":"Fineran PC. Resistance is not futile: bacterial 'innate' and CRISPR-Cas 'adaptive' immune systems. Microbiology (Reading). 2019, 165:834-41. 10.1099\/mic.0.000802","journal-title":"Microbiology (Reading)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/308502-induced-native-phage-cocktails-for-multi-microbial-activation-syndrome-in-treatment-resistant-illnesses","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T03:39:08Z","timestamp":1730173148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/308502-induced-native-phage-cocktails-for-multi-microbial-activation-syndrome-in-treatment-resistant-illnesses"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.72587","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,28]]}}}